Methods and systems for inhibiting vascular inflammation
First Claim
1. A method for inhibiting inflammation in a patient'"'"'s vasculature, said method comprising:
- positioning a catheter within a lumen of a blood vessel of the patient, the blood vessel having had a revascularization procedure performed thereon;
advancing a needle radially outwardly from the catheter through a wall of the blood vessel and into an adventitial tissue surrounding the blood vessel; and
delivering an anti-inflammatory agent into the adventitial tissue and a perivascular tissue through the needle advanced into the adventitial tissue in an amount sufficient to inhibit inflammation of the blood vessel after the revascularization procedure, wherein the anti-inflammatory agent consists essentially of dexamethasone or dexamethasone phosphate,wherein the inhibition or a reduction of inflammation is characterized by a detectable lack of a significant increase or a detectable reduction, respectively, in monocyte chemotractive protein-1 (MCP-1) levels in circulating blood.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods and kits for delivering pharmaceutical agents to an adventitia and other regions outside an external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of a pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent. In one example, catheters are used to deliver dexamethasone and other anti-inflammatory agents to a peripheral vasculature and other vasculature to treat peripheral vascular disease and other conditions.
-
Citations
33 Claims
-
1. A method for inhibiting inflammation in a patient'"'"'s vasculature, said method comprising:
-
positioning a catheter within a lumen of a blood vessel of the patient, the blood vessel having had a revascularization procedure performed thereon; advancing a needle radially outwardly from the catheter through a wall of the blood vessel and into an adventitial tissue surrounding the blood vessel; and delivering an anti-inflammatory agent into the adventitial tissue and a perivascular tissue through the needle advanced into the adventitial tissue in an amount sufficient to inhibit inflammation of the blood vessel after the revascularization procedure, wherein the anti-inflammatory agent consists essentially of dexamethasone or dexamethasone phosphate, wherein the inhibition or a reduction of inflammation is characterized by a detectable lack of a significant increase or a detectable reduction, respectively, in monocyte chemotractive protein-1 (MCP-1) levels in circulating blood. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
-
18. A method for inhibiting inflammation in a patient'"'"'s vasculature, said method comprising:
-
positioning a catheter within a lumen of a blood vessel of the patient, the blood vessel having had a revascularization procedure performed thereon; advancing a needle radially outwardly from the catheter through a wall of the blood vessel and into an adventitial tissue surrounding the blood vessel; and delivering an anti-inflammatory agent into the adventitial tissue and a perivascular tissue through the advanced needle in an amount sufficient to inhibit inflammation of the blood vessel after the revascularization procedure, wherein the anti-inflammatory agent comprises dexamethasone or dexamethasone phosphate, and wherein the dexamethasone or the dexamethasone phosphate is delivered into the adventitial tissue and the perivascular tissue at a dosage of 0.5 to 2.7 mg per cm of lesion, wherein the inhibition or a reduction of inflammation is characterized by a detectable lack of a significant increase or a detectable reduction, respectively, in monocyte chemotractive protein-1 (MCP-1) levels in circulating blood. - View Dependent Claims (19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
Specification